SEC Filing Summary: PerkinElmer, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PerkinElmer, Inc. on November 20, 2007, covering events that occurred on November 14, 2007. The filing details the completion of a strategic acquisition and the financing arrangements established to fund the transaction.
Key Financial Metrics and Transaction Details
- Acquisition Cost: PerkinElmer paid approximately $313 million in cash to acquire all outstanding shares of ViaCell, Inc., including fees and expenses.
- Financing Structure: The company entered into a $300 million unsecured interim credit facility (bridge loan) with Bank of America, N.A. as Administrative Agent.
- Debt Utilization: PerkinElmer drew down the full $300 million available under the facility on November 14, 2007.
- Interest Terms: Interest is based on the Eurocurrency rate plus a margin of 62.5 basis points or the base rate (higher of corporate base rate or Federal Funds rate plus 50 basis points).
- Maturity Date: The interim facility matures on March 31, 2008, with all amounts due in full.
- Default Rate: In the event of non-payment, the interest rate increases by 2%.
Material Changes
The primary material change is the addition of ViaCell, Inc. as a wholly-owned subsidiary and the corresponding increase in short-term indebtedness. The filing does not provide comparative financial metrics (revenue, profit, or cash flow) for the prior period as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Covenants
- Covenants: The Credit Agreement includes affirmative, negative, and financial covenants customary for this type of financing.
- Prepayment Requirements: PerkinElmer must prepay the loan with net cash proceeds from any new equity issuance or additional indebtedness incurred outside the ordinary course of business.
- Liquidity Risk: The entire $300 million principal is due on March 31, 2008, creating a refinancing or repayment obligation within six months of the filing.
- Management Commentary: The filing does not contain forward-looking guidance or management commentary regarding future earnings or operational outlook beyond the transaction details.
Investor Verification Checklist
- Verify the source of funds for the remaining $13 million of the purchase price not covered by the $300 million bridge loan.
- Confirm PerkinElmer's plan to refinance the $300 million interim facility before the March 31, 2008 maturity date.
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific financial covenants that could restrict future operations.
- Assess the strategic fit and expected financial contribution of ViaCell, Inc. to PerkinElmer's portfolio.